Key result
Authorized generic celecoxib was dominant compared to loxoprofen for chronic pain management over a lifetime horizon, yielding a cost reduction of 6,268 JPY and an incremental QALY gain of 0.024 per patient.
Why the study?
The cost-effectiveness of branded and authorized generic celecoxib compared with loxoprofen in patients with chronic pain had not been evaluated using real-world cost data in Japan.
Is branded or authorized generic celecoxib cost-effective compared to loxoprofen for patients with chronic pain in Japan?
Is branded or authorized generic celecoxib cost-effective compared to loxoprofen for patients with chronic pain in Japan?
Authorized generic celecoxib is a cost-saving option compared to loxoprofen for chronic pain management in Japan when considering the future risk of gastrointestinal injury.
May support AG celecoxib consideration for chronic pain in Japan; leaves open prospective validation of modeling assumptions.
OBJECTIVES: The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding. METHODS: This cost-effectiveness analysis was performed as a long-term simulation using the Markov model from the Japanese public healthcare payer's perspective. The analysis was conducted using loxoprofen with real-world weighted price by branded/generic distribution (hereinafter, loxoprofen with weighted price) as a comparator. In the model, we simulated the prognosis of patients with chronic pain by OA, RA, and LBP treated with loxoprofen or celecoxib, over a lifetime period. RESULTS: A cost-increase of 129,688 JPY (1,245.00 USD) for branded celecoxib and a cost-reduction of 6,268 JPY (60.17 USD) for AG celecoxib were recognized per patient in lifetime horizon, compared to loxoprofen with weighted price. No case was recognized to reverse the results of cost-saving by AG celecoxib in one-way sensitivity analysis. The incremental cost-effectiveness ratio of branded celecoxib attained 5,403,667 JPY/QALY (51,875.20 USD/QALY), compared to loxoprofen with the weighted price. CONCLUSION: The current cost-effectiveness analysis for AG celecoxib revealed its good value for costs, considering the patients' future risk of gastrointestinal injury; also, the impact on costs due to AG celecoxib against loxoprofen will be small. It implies that the disadvantage of AG celecoxib being slightly more expensive than generic loxoprofen could be offset by the good cost-effectiveness during the prognosis.
No takes yet. Share an insight, caveat, or question.
Karasawa et al. (2021) studied Chronic pain (osteoarthritis, rheumatoid arthritis, low back pain). Authorized generic (AG) celecoxib vs. Loxoprofen (180 mg/day) was evaluated on Incremental cost-effectiveness ratio (ICER) (Dominant). Authorized generic celecoxib was dominant compared to loxoprofen for chronic pain management over a lifetime horizon, yielding a cost reduction of 6,268 JPY and an incremental QALY gain of 0.024 per patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: